Literatur
-
01
Pitt B .
Gheorghiade M .
Zannad F .
et al .
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%.
Eur J Heart Fail.
2006;
8 (3)
295-301
-
02
Pitt B .
Remme W .
Zannad F .
et al .
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med.
2003;
348 (14)
1309-1321
-
03
Pitt B .
White H .
Nicolau J .
et al .
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
J Am Coll Cardiol.
2005;
46 (3)
425-431
-
04
Steg G .
Dabbous OH .
Feldman LJ .
et al .
Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE).
Circulation.
2004;
109 (4)
494-499
1 Eplerenone Post-AMI Heart failure Efficacy and SUrvival Study
